论文部分内容阅读
目的 观察前列地尔注射液改善慢性肝病的炎症及抗肝纤维化的作用。方法 42 5例慢性肝病随机分为治疗组 2 2 0例 ,对照组 2 0 5例 ,两组均采用相同的基础疗法。治疗组加用前列地尔 2 0ug加入 1 0 %葡萄糖 2 50ml,缓慢静脉滴注 ,每天 1次 ,1疗程结束复查透明质酸 (HA)、Ⅲ型前胶原 (PC -Ⅲ )、Ⅳ型胶原 (1V -C)、谷丙转氨酶(ALT) ,总胆红素 (TB) ,白蛋白 (A) ,球蛋白 (G)。结果 两组治疗前后比较P <0 .0 0 1 ,治疗组在降HA、PC -III、IV -C及改善肝功能方面明显优于对照组P <0 .0 0 1。结论 前列地尔对降低慢性肝病HA、PC -Ⅲ、IV -C有确切疗效
Objective To observe the effect of alprostadil injection on inflammation and anti-hepatic fibrosis in chronic liver disease. Methods 42 cases of chronic liver disease were randomly divided into treatment group 220 cases, control group 205 cases, both groups were using the same basic therapy. The treatment group plus alprostadil 20ug added 10% glucose 2 50ml, slow intravenous infusion, once a day, after a course of treatment review of hyaluronic acid (HA), type Ⅲ procollagen (PC-Ⅲ), type Ⅳ collagen (1V -C), alanine aminotransferase (ALT), total bilirubin (TB), albumin (A), globulin (G). Results Before and after treatment, P <0.01, the treatment group was significantly better than the control group in reducing HA, PC-III, IV-C and improving liver function P <0.01. Conclusion Alprostadil has definite curative effect on reducing HA, PC-Ⅲ and IV-C of chronic liver disease